By 
Mason Wakley2026-10-07T08:44:00
Danish firm aims to bolster pipeline of weight-loss and metabolic disease therapies
Novo Nordisk has struck several deals collectively worth over £4 billion to secure rights to several weight-loss and cardiometabolic disease treatments. Novo’s deal spree is likely an attempt to curb anticipated revenue loss as the patent on semaglutide – the active ingredient in Novo’s Wegovy and Ozempic, marketed for weight loss and diabetes respectively – has expired in several countries and is set to expire in Europe and the US over the next few years.
